보고서 요약(국문)

시장 개요
전 세계 폐동맥 고혈압 시장 규모는 2022년 70억 달러였으며, 2030년까지 106억 달러에 이를 것으로 예상됩니다. 2023년부터 2030년까지 연평균 성장률(CAGR)은 5.3%입니다. 폐동맥 고혈압은 완치할 수는 없지만, 약물 치료를 통해 증상을 완화하고 환자들이 질환을 관리할 수 있도록 도울 수 있습니다.
폐동맥 고혈압은 시간이 지남에 따라 악화되는 경우가 많습니다. 치료하지 않고 방치하면 심부전으로 이어져 사망에 이를 수 있으므로 가능한 한 빨리 치료를 시작해야 합니다. 폐동맥 고혈압이 다른 질환으로 인해 발생한 경우, 기저 질환을 먼저 치료해야 합니다. 이렇게 하면 폐동맥에 영구적인 손상을 예방할 수 있습니다.
시장 동향
노년층 환자의 발병률 증가
노년층 환자의 발병률 증가는 폐동맥 고혈압 시장 성장을 촉진하는 주요 요인 중 하나입니다. 예를 들어, 최근 연구에 따르면 미국과 유럽의 통계 자료에서 폐동맥 고혈압이 다른 심혈관 질환을 동반하는 고령층에서 점점 더 많이 발견되고 있는 것으로 나타났습니다. 이 연구에서는 폐동맥 고혈압 진단 시 평균 연령이 60세였으며, 환자의 29%가 70세 이상인 것으로 밝혀졌습니다.
폐동맥 고혈압 치료 비용의 높은 부담
폐동맥 고혈압 치료 비용이 높은 것은 폐동맥 고혈압 시장 성장을 저해하는 요인 중 하나입니다. 연구에 따르면 폐동맥 고혈압 환자는 과도한 약물 사용으로 인해 약제비가 많이 발생합니다.¹ 더욱이, 폐동맥 고혈압은 주사제로 치료되는 경우가 많은데, 이러한 약물은 의료 혜택으로 청구되지만 비용에 대한 투명성이 부족한 경우가 많습니다.

폐동맥 고혈압(PAH)에 대한 병용 요법은 상당히 흔합니다. PAH 환자의 46%가 이중 요법을, 9%가 삼중 요법을 받고 있으며, 이는 잠재적으로 의료비 부담을 증가시킵니다.2 이중 및 삼중 요법에 대한 중요한 임상 시험인 TRITON은 기준치 대비 폐혈관 저항(PVR)의 유의미한 감소를 보여주었으며, 이전의 단계적 치료 강화보다 우수한 결과를 나타냈습니다.3,4 이러한 환자들은 더 오래 살고 폐 이식의 필요성을 피하고 있습니다.
COVID-19 영향 분석
COVID-19 관련 폐동맥 고혈압의 주요 원인 기전은 3군 폐동맥 고혈압에서 나타나는 광범위한 폐 손상(간질 및 폐포 염증으로 인한)과 4군 폐동맥 고혈압에서 나타나는 폐혈관 변화(혈전/혈전색전 과정, 내피 손상 또는 최소한 저산소성 혈관 수축으로 인한)로 여겨지지만, 경우에 따라 기계 환기 시 사용되는 양압 호흡(PEEP)의 영향도 추가적인 요인이 될 수 있습니다.
세분화 분석
차세대 콘택트렌즈 및 시각 보철 시장은 전 세계적으로 약물 종류, 투여 경로 및 유통 채널별로 세분화됩니다.
경구 투여 경로 부문은 예측 기간 동안 시장 참여자들에 의해 주도될 것입니다.

경구 투여 경로 부문은 약 44.3%의 점유율로 예측 기간 동안 시장 참여자들의 제품이 지배적인 위치를 차지할 것으로 예상됩니다. 이는 가장 널리 사용되는 약물 투여 방식이기 때문입니다. 경구 투여는 비침습성, 환자 순응도, 편리한 투약 등의 장점으로 인해 선호되는 방법입니다. 약물의 용해도, 점막 투명도, 소화기계 환경의 안정성은 모두 경구 약물 흡수에 영향을 미치는 변수입니다.
흡입 약물은 특정 수용체를 표적으로 하기 때문에 전신 치료제(경구 또는 주사)보다 낮은 용량으로 투여할 수 있어 부작용이 적습니다. 임상적 효능 측면에서 세 가지 유형의 에어로졸 기기(MDI, DPI, 네뷸라이저)는 유사할 수 있습니다. 따라서 흡입 투여 시장은 가장 빠르게 성장하는 분야가 될 것으로 예상됩니다.
지역 분석
북미는 예측 기간 동안 시장을 주도할 지역입니다.
북미는 매출 점유율 기준으로 예측 기간 동안 전체 시장 점유율의 약 39.1%를 차지할 것으로 추정됩니다. 이 지역의 선진적인 의료 시스템은 혁신적인 치료법에 대한 접근성을 제공하며, 이는 시장 성장의 상당 부분을 차지합니다. 인식 제고, 높은 진단율, 그리고 우호적인 정부 정책 또한 시장 발전에 기여하고 있습니다.
북미에서는 폐고혈압이 일반적으로 폐 전문의, 심장 전문의, 폐고혈압 전문의와 같은 전문 의료진에 의해 진단 및 관리됩니다. 이들은 환자와 협력하여 약물, 생활 습관 개선, 그리고 특정 상황에서는 폐동맥 고혈압(PAH) 표적 치료제, 프로스타사이클린 유사체, 폐 이식과 같은 고도의 치료법을 포함하는 맞춤형 치료 프로그램을 수립합니다.
경쟁 환경
주요 글로벌 기업으로는 Arena Pharmaceuticals, Bayer AG, Bristol-Myers Squibb Company, Gilead Sciences Inc, GlaxoSmithKline Plc, Actelion Pharmaceuticals, Ltd. (Johnson & Johnson), Merck & Co. Inc, Novartis International AG, Pfizer Inc, United Therapeutics Corporation 등이 있습니다.
• 보고서를 구매해야 하는 이유

• 약물 종류, 투여 경로, 유통 채널 및 지역별 글로벌 폐동맥 고혈압 시장 세분화를 시각화하고 주요 상업 자산 및 주요 업체를 파악합니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 발굴합니다.

• 모든 세그먼트를 포함한 글로벌 폐동맥 고혈압 시장 수준의 다양한 데이터가 담긴 엑셀 자료를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품을 포함한 제품 맵핑 자료를 엑셀 파일로 제공합니다.

글로벌 폐동맥 고혈압 시장 보고서는 약 92개의 표, 108개의 그림, 195페이지 분량입니다.
주요 대상 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 연구 전문가
• 신흥 기업

보고서 요약(영어 원문)

Market Overview
The Global Pulmonary Arterial Hypertension Market size was worth US$ 7 billion in 2022 and is estimated to reach US$ 10.6 billion by 2030, growing at a CAGR of 5.3% during the forecast period 2023-2030. Although pulmonary hypertension cannot be cured, medication may reduce symptoms and assist patients in managing the condition.
Pulmonary hypertension often worsens over time. If left untreated, it can lead to cardiac failure, which can be deadly. Thus, treatment should begin as soon as possible. If pulmonary hypertension is caused by another ailment, the underlying condition should be addressed first. This can occasionally avoid lasting damage to the pulmonary arteries.
Market Dynamics
Increased rate of disease of in Geriatric patients
Increased rate of disease in Geriatric patients is one the driver that increases the market growth of the pulmonary arterial hypertension market. For instance, a recent study found that statistics from the United States and Europe show that pulmonary arterial hypertension is increasingly being detected in older individuals, who commonly have other cardiovascular comorbidities. During the study, it was discovered that the median age at the time of diagnosis of pulmonary arterial hypertension was 60 years, and 29% of the patients were 70 years or older.
High cost of treatment of Pulmonary arterial hypertension
High cost of treatment of Pulmonary arterial hypertension is one of the markets hinder which stops the Pulmonary arterial hypertension market for instance, According to studies, individuals with PAH have large pharmacy expenses due to excessive medication use.1 To complicate matters, PAH is frequently treated using injected medications that might be billed under the medical benefit with minimal visibility to cost.
Combination therapy for PAH is fairly common: 46 percent of PAH patients are on dual therapy regimens, and 9 percent are on triple therapy regimens, potentially raising payor expenses.2 TRITON, a crucial trial on double and triple therapy, exhibited significant reductions in pulmonary vascular resistance (PVR) relative to baseline, outperforming previous progressive therapy escalation.3,4 These people are enjoying longer lives and avoiding the need for lung transplants.
COVID-19 Impact Analysis
Covid possesses the main responsible mechanisms for Pulmonary Arterial Hypertension associated with COVID-19 are considered extensive pulmonary damage (due to interstitial and alveolar inflammation) as in PAH of group 3 and alterations in pulmonary vasculature (induced by thrombotic/thromboembolic processes, endothelial injury, or, at the very least, hypoxic vasoconstriction) as in PAH of group 4, but in some cases, an additional factor could be the consequences of positive end-Ex expiratory pressure used in mechanical ventilation.
Segment Analysis
The market for next-generation contact lenses and visual prostheses is segmented by drug class, route of administration, and distribution channel on a global scale.
The Oral Route Of the Administration Segment will be Dominated By Market Players During the Forecast Period.
The Oral route segment, with a percentage of around 44.3%, is dominated by market players’ products during the forecast period as it is the most prevalent form of drug administration. It is the preferred method because to its advantages, such as non-invasiveness, patient compliance, and convenience of medicine administration. Medication solubility, mucosal transparency, and the stability of the digestive system environment are all variables that impact oral medication absorption.
Because inhaled drugs specifically target the receptor, they can be supplied at a lower dose than systemic therapies (oral or injectable), resulting in less mild adverse effects. Regarding clinical efficacy, the three types of aerosol devices (MDI, DPI, and nebulizer) may be comparable. As a result, the market for inhalational administration is likely to be the fastest-growing sector.
Geographical Analysis
North America is the dominating region during the forecast period.
North America is estimated to hold around 39.1% of the total market share throughout the forecast period in terms of revenue share. The sophisticated healthcare system in the region, which offers access to innovative therapies, is responsible for a large portion of this. Increased awareness, a high incidence of diagnosis, and favorable government policies contribute to market development.
In North America, pulmonary hypertension is normally diagnosed and managed by specialized healthcare experts such as pulmonologists, cardiologists, and PH specialists. They collaborate with patients to create personalized treatment programs that may include medicines, lifestyle changes, and, in certain situations, sophisticated treatments, including pulmonary arterial hypertension (PAH)-targeted pharmaceuticals, prostacyclin analogs, or lung transplantation.
Competitive Landscape
The major global players include Arena Pharmaceuticals, Bayer AG, Bristol-Myers Squibb Company, Gilead Sciences Inc GlaxoSmithKline Plc, Actelion Pharmaceuticals, Ltd. (Johnson & Johnson), Merck & Co. Inc, Novartis International AG, Pfizer Inc, United Therapeutics Corporation
• Why Purchase the Report?
• To visualize the Global Pulmonary Arterial Hypertension Market segmentation based on the drug class, Route of administration and Distribution channel and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous Global Pulmonary Arterial Hypertension Market level data points with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.
The Global Pulmonary Arterial Hypertension Market Report Would Provide Approximately 92 Tables, 108 Figures And 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by drug class
3.2. Snippet by Route of administration
3.3. Snippet by Distribution channel
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increase rate of disease in geriatric patients
4.1.2. Restraints
4.1.2.1. High cost of treatment of pulmonary arterial hypertension
4.1.3. Opportunity
4.1.3.1. Rapid growing generic drug market
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's 5 forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Post COVID-19 & Future Scenario
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion
7. By Drug Class
7.1 Prostacyclin and Prostacyclin Analogs
7.2 Calcium Channel Blockers
7.3 Phosphodiesterase 5 (PDE-5)
7.4 Endothelin Receptor Antagonists (ERA)
7.5 Others
8. By Route of Administration
8.1. Inhalation
8.2. Injectable
8.3. Oral Administration
9. By Distribution Channel
9.1. Hospital Pharmacy
9.2. Pharmacy Stores
9.3. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. The U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. The UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Arena Pharmaceuticals
12.3. Bayer AG
12.4. Bristol-Myers Squibb Company
12.5. Gilead Sciences Inc
12.6. GlaxoSmithKline Plc
12.7. Actelion Pharmaceuticals, Ltd. (Johnson & Johnson)
12.8. Merck & Co. Inc
12.9. Novartis International AG
12.10. Pfizer Inc
12.11. United Therapeutics Corporation
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

Arena Pharmaceuticals, Bayer AG, Bristol-Myers Squibb Company, Gilead Sciences Inc, GlaxoSmithKline Plc, Actelion Pharmaceuticals, Ltd. (Johnson & Johnson), Merck & Co. Inc, Novartis International AG, Pfizer Inc, United Therapeutics Corporation

표 목록 (Tables)

List of Tables Table 1 Global Pulmonary Arterial Hypertension Market Value, By Drug Class, 2025, 2029 & 2033 (US$ Billion)

Table 2 Global Pulmonary Arterial Hypertension Market Value, By Route of Administration, 2025, 2029 & 2033 (US$ Billion)

Table 3 Global Pulmonary Arterial Hypertension Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Billion)

Table 4 Global Pulmonary Arterial Hypertension Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)

Table 5 Global Pulmonary Arterial Hypertension Market Value, By Drug Class, 2025, 2029 & 2033 (US$ Billion)

Table 6 Global Pulmonary Arterial Hypertension Market Value, By Drug Class, 2022-2033 (US$ Billion)

Table 7 Global Pulmonary Arterial Hypertension Market Value, By Route of Administration, 2025, 2029 & 2033 (US$ Billion)

Table 8 Global Pulmonary Arterial Hypertension Market Value, By Route of Administration, 2022-2033 (US$ Billion)

Table 9 Global Pulmonary Arterial Hypertension Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Billion)

Table 10 Global Pulmonary Arterial Hypertension Market Value, By Distribution Channel, 2022-2033 (US$ Billion)

Table 11 Global Pulmonary Arterial Hypertension Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)

Table 12 Global Pulmonary Arterial Hypertension Market Value, By Region, 2022-2033 (US$ Billion)

Table 13 North America Pulmonary Arterial Hypertension Market Value, By Drug Class, 2022-2033 (US$ Billion)

Table 14 North America Pulmonary Arterial Hypertension Market Value, By Route of Administration, 2022-2033 (US$ Billion)

Table 15 North America Pulmonary Arterial Hypertension Market Value, By Distribution Channel, 2022-2033 (US$ Billion)

Table 16 North America Pulmonary Arterial Hypertension Market Value, By Country, 2022-2033 (US$ Billion)

Table 17 Europe Pulmonary Arterial Hypertension Market Value, By Drug Class, 2022-2033 (US$ Billion)

Table 18 Europe Pulmonary Arterial Hypertension Market Value, By Route of Administration, 2022-2033 (US$ Billion)

Table 19 Europe Pulmonary Arterial Hypertension Market Value, By Distribution Channel, 2022-2033 (US$ Billion)

Table 20 Europe Pulmonary Arterial Hypertension Market Value, By Country, 2022-2033 (US$ Billion)

Table 21 Asia-Pacific Pulmonary Arterial Hypertension Market Value, By Drug Class, 2022-2033 (US$ Billion)

Table 22 Asia-Pacific Pulmonary Arterial Hypertension Market Value, By Route of Administration, 2022-2033 (US$ Billion)

Table 23 Asia-Pacific Pulmonary Arterial Hypertension Market Value, By Distribution Channel, 2022-2033 (US$ Billion)

Table 24 Asia-Pacific Pulmonary Arterial Hypertension Market Value, By Country, 2022-2033 (US$ Billion)

Table 25 South America Pulmonary Arterial Hypertension Market Value, By Drug Class, 2022-2033 (US$ Billion)

Table 26 South America Pulmonary Arterial Hypertension Market Value, By Route of Administration, 2022-2033 (US$ Billion)

Table 27 South America Pulmonary Arterial Hypertension Market Value, By Distribution Channel, 2022-2033 (US$ Billion)

Table 28 South America Pulmonary Arterial Hypertension Market Value, By Country, 2022-2033 (US$ Billion)

Table 29 Middle East and Africa Pulmonary Arterial Hypertension Market Value, By Drug Class, 2022-2033 (US$ Billion)

Table 30 Middle East and Africa Pulmonary Arterial Hypertension Market Value, By Route of Administration, 2022-2033 (US$ Billion)

Table 31 Middle East and Africa Pulmonary Arterial Hypertension Market Value, By Distribution Channel, 2022-2033 (US$ Billion)

Table 32 Middle East and Africa Pulmonary Arterial Hypertension Market Value, By Country, 2022-2033 (US$ Billion)

Table 33 Johnson & Johnson: Overview

Table 34 Johnson & Johnson: Product Portfolio

Table 35 Johnson & Johnson: Key Developments

Table 36 United Therapeutics Corporation: Overview

Table 37 United Therapeutics Corporation: Product Portfolio

Table 38 United Therapeutics Corporation: Key Developments

Table 39 Bayer AG: Overview

Table 40 Bayer AG: Product Portfolio

Table 41 Bayer AG: Key Developments

Table 42 Gilead Sciences, Inc.: Overview

Table 43 Gilead Sciences, Inc.: Product Portfolio

Table 44 Gilead Sciences, Inc.: Key Developments

Table 45 Viatris Inc.: Overview

Table 46 Viatris Inc.: Product Portfolio

Table 47 Viatris Inc.: Key Developments

Table 48 Merck & Co., Inc.: Overview

Table 49 Merck & Co., Inc.: Product Portfolio

Table 50 Merck & Co., Inc.: Key Developments

Table 51 Liquidia Corporation: Overview

Table 52 Liquidia Corporation: Product Portfolio

Table 53 Liquidia Corporation: Key Developments

그림 목록 (Figures)

List of Figures Figure 1 Global Pulmonary Arterial Hypertension Market Value, 2022-2033 (US$ Billion)

Figure 2 Global Pulmonary Arterial Hypertension Market Share, By Drug Class, 2024 & 2033 (%)

Figure 3 Global Pulmonary Arterial Hypertension Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 4 Global Pulmonary Arterial Hypertension Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 5 Global Pulmonary Arterial Hypertension Market Share, By Region, 2024 & 2033 (%)

Figure 6 Global Pulmonary Arterial Hypertension Market Y-o-Y Growth, By Drug Class, 2023-2033 (%)

Figure 7 Prostacyclin and Prostacyclin Analogs Pulmonary Arterial Hypertension Market Value, 2022-2033 (US$ Billion)

Figure 8 Calcium Channel Blockers Pulmonary Arterial Hypertension Market Value, 2022-2033 (US$ Billion)

Figure 9 Phosphodiesterase-5 (PDE-5) Inhibitors Pulmonary Arterial Hypertension Market Value, 2022-2033 (US$ Billion)

Figure 10 Endothelin Receptor Antagonists (ERA) Pulmonary Arterial Hypertension Market Value, 2022-2033 (US$ Billion)

Figure 11 Others Pulmonary Arterial Hypertension Market Value, 2022-2033 (US$ Billion)

Figure 12 Global Pulmonary Arterial Hypertension Market Y-o-Y Growth, By Route of Administration, 2023-2033 (%)

Figure 13 Inhalation Route of Administration in Global Pulmonary Arterial Hypertension Market Value, 2022-2033 (US$ Billion)

Figure 14 Subcutaneous and Intravenous Route of Administration in Global Pulmonary Arterial Hypertension Market Value, 2022-2033 (US$ Billion)

Figure 15 Oral Route of Administration in Global Pulmonary Arterial Hypertension Market Value, 2022-2033 (US$ Billion)

Figure 16 Global Pulmonary Arterial Hypertension Market Y-o-Y Growth, By Distribution Channel, 2023-2033 (%)

Figure 17 Hospital Pharmacies Distribution Channel in Global Pulmonary Arterial Hypertension Market Value, 2022-2033 (US$ Billion)

Figure 18 Retail Pharmacies Distribution Channel in Global Pulmonary Arterial Hypertension Market Value, 2022-2033 (US$ Billion)

Figure 19 Online Pharmacies Distribution Channel in Global Pulmonary Arterial Hypertension Market Value, 2022-2033 (US$ Billion)

Figure 20 Global Pulmonary Arterial Hypertension Market Y-o-Y Growth, By Region, 2023-2033 (%)

Figure 21 North America Pulmonary Arterial Hypertension Market Value, 2022-2033 (US$ Billion)

Figure 22 North America Pulmonary Arterial Hypertension Market Share, By Drug Class, 2024 & 2033 (%)

Figure 23 North America Pulmonary Arterial Hypertension Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 24 North America Pulmonary Arterial Hypertension Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 25 North America Pulmonary Arterial Hypertension Market Share, By Country, 2024 & 2033 (%)

Figure 26 Europe Pulmonary Arterial Hypertension Market Value, 2022-2033 (US$ Billion)

Figure 27 Europe Pulmonary Arterial Hypertension Market Share, By Drug Class, 2024 & 2033 (%)

Figure 28 Europe Pulmonary Arterial Hypertension Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 29 Europe Pulmonary Arterial Hypertension Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 30 Europe Pulmonary Arterial Hypertension Market Share, By Country, 2024 & 2033 (%)

Figure 31 Asia-Pacific Pulmonary Arterial Hypertension Market Value, 2022-2033 (US$ Billion)

Figure 32 Asia-Pacific Pulmonary Arterial Hypertension Market Share, By Drug Class, 2024 & 2033 (%)

Figure 33 Asia-Pacific Pulmonary Arterial Hypertension Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 34 Asia-Pacific Pulmonary Arterial Hypertension Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 35 Asia-Pacific Pulmonary Arterial Hypertension Market Share, By Country, 2024 & 2033 (%)

Figure 36 South America Pulmonary Arterial Hypertension Market Value, 2022-2033 (US$ Billion)

Figure 37 South America Pulmonary Arterial Hypertension Market Share, By Drug Class, 2024 & 2033 (%)

Figure 38 South America Pulmonary Arterial Hypertension Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 39 South America Pulmonary Arterial Hypertension Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 40 South America Pulmonary Arterial Hypertension Market Share, By Country, 2024 & 2033 (%)

Figure 41 Middle East and Africa Pulmonary Arterial Hypertension Market Value, 2022-2033 (US$ Billion)

Figure 42 Middle East and Africa Pulmonary Arterial Hypertension Market Share, By Drug Class, 2024 & 2033 (%)

Figure 43 Middle East and Africa Pulmonary Arterial Hypertension Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 44 Middle East and Africa Pulmonary Arterial Hypertension Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 45 Johnson & Johnson: Financials

Figure 46 United Therapeutics Corporation: Financials

Figure 47 Bayer AG: Financials

Figure 48 Gilead Sciences, Inc.: Financials

Figure 49 Viatris Inc.: Financials

Figure 50 Merck & Co., Inc.: Financials

Figure 51 Liquidia Corporation: Financials

세계 폐동맥 고혈압 시장 – 2023-2030

Global Pulmonary Arterial Hypertension Market - 2023-2030